Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients

Li Heng Yang, Hsin Shun Tseng, Che Lin, Li Sheng Chen, Shou Tung Chen, Shou Jen Kuo, Dar Ren Chen

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Purpose: This study aimed to analyze the efficacy and prognostic significance of adjuvant tamoxifen in breast cancer patients with various hormone receptor statuses. Methods: Typically, 1,260 female breast cancer patients were recruited in this study. The correlation between estrogen receptor (ER)/progesterone receptor (PR) phenotypes and clinical characteristics was investigated, and the survival rate was assessed after 5-year follow-up. Results: The 5-year overall survival (85%) was better in women under the age of 50 years. Patients with ER+/PR+ tumors had a better 5-year survival rate (94%); those with ER-/PRtumors experienced the worst outcome (74% survival rate); whereas singlepositive cases were in between. In 97 out of 128 patients with ER-/PR+ tumors, tamoxifen was given as adjuvant hormonal therapy, and it increased the survival benefit in the lower grade group in terms of overall survival and disease-free survival (p= 0.01 and p=0.03, respectively). Conclusion: For high-grade tumors with ER-/PR+, adjuvant tamoxifen therapy may have no survival benefit, whereas for the patients with low-grade ER-/ PR+ tumors, adjuvant tamoxifen therapy is highly suggestive.

Original languageEnglish
Pages (from-to)288-295
Number of pages8
JournalJournal of Breast Cancer
Volume15
Issue number3
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Progesterone Receptors
Tamoxifen
Estrogen Receptors
Breast Neoplasms
Survival
Survival Rate
Neoplasms
Disease-Free Survival
Therapeutics
Hormones
Phenotype

Keywords

  • Breast carcinoma
  • Estrogen receptor
  • Progesterone receptor
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients. / Yang, Li Heng; Tseng, Hsin Shun; Lin, Che; Chen, Li Sheng; Chen, Shou Tung; Kuo, Shou Jen; Chen, Dar Ren.

In: Journal of Breast Cancer, Vol. 15, No. 3, 09.2012, p. 288-295.

Research output: Contribution to journalArticle

Yang, Li Heng ; Tseng, Hsin Shun ; Lin, Che ; Chen, Li Sheng ; Chen, Shou Tung ; Kuo, Shou Jen ; Chen, Dar Ren. / Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients. In: Journal of Breast Cancer. 2012 ; Vol. 15, No. 3. pp. 288-295.
@article{e991d9c473584fb69bdf399ffc837dfe,
title = "Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients",
abstract = "Purpose: This study aimed to analyze the efficacy and prognostic significance of adjuvant tamoxifen in breast cancer patients with various hormone receptor statuses. Methods: Typically, 1,260 female breast cancer patients were recruited in this study. The correlation between estrogen receptor (ER)/progesterone receptor (PR) phenotypes and clinical characteristics was investigated, and the survival rate was assessed after 5-year follow-up. Results: The 5-year overall survival (85{\%}) was better in women under the age of 50 years. Patients with ER+/PR+ tumors had a better 5-year survival rate (94{\%}); those with ER-/PRtumors experienced the worst outcome (74{\%} survival rate); whereas singlepositive cases were in between. In 97 out of 128 patients with ER-/PR+ tumors, tamoxifen was given as adjuvant hormonal therapy, and it increased the survival benefit in the lower grade group in terms of overall survival and disease-free survival (p= 0.01 and p=0.03, respectively). Conclusion: For high-grade tumors with ER-/PR+, adjuvant tamoxifen therapy may have no survival benefit, whereas for the patients with low-grade ER-/ PR+ tumors, adjuvant tamoxifen therapy is highly suggestive.",
keywords = "Breast carcinoma, Estrogen receptor, Progesterone receptor, Tamoxifen",
author = "Yang, {Li Heng} and Tseng, {Hsin Shun} and Che Lin and Chen, {Li Sheng} and Chen, {Shou Tung} and Kuo, {Shou Jen} and Chen, {Dar Ren}",
year = "2012",
month = "9",
doi = "10.4048/jbc.2012.15.3.288",
language = "English",
volume = "15",
pages = "288--295",
journal = "Journal of Breast Cancer",
issn = "1738-6756",
publisher = "Korean Breast Cancer Society",
number = "3",

}

TY - JOUR

T1 - Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients

AU - Yang, Li Heng

AU - Tseng, Hsin Shun

AU - Lin, Che

AU - Chen, Li Sheng

AU - Chen, Shou Tung

AU - Kuo, Shou Jen

AU - Chen, Dar Ren

PY - 2012/9

Y1 - 2012/9

N2 - Purpose: This study aimed to analyze the efficacy and prognostic significance of adjuvant tamoxifen in breast cancer patients with various hormone receptor statuses. Methods: Typically, 1,260 female breast cancer patients were recruited in this study. The correlation between estrogen receptor (ER)/progesterone receptor (PR) phenotypes and clinical characteristics was investigated, and the survival rate was assessed after 5-year follow-up. Results: The 5-year overall survival (85%) was better in women under the age of 50 years. Patients with ER+/PR+ tumors had a better 5-year survival rate (94%); those with ER-/PRtumors experienced the worst outcome (74% survival rate); whereas singlepositive cases were in between. In 97 out of 128 patients with ER-/PR+ tumors, tamoxifen was given as adjuvant hormonal therapy, and it increased the survival benefit in the lower grade group in terms of overall survival and disease-free survival (p= 0.01 and p=0.03, respectively). Conclusion: For high-grade tumors with ER-/PR+, adjuvant tamoxifen therapy may have no survival benefit, whereas for the patients with low-grade ER-/ PR+ tumors, adjuvant tamoxifen therapy is highly suggestive.

AB - Purpose: This study aimed to analyze the efficacy and prognostic significance of adjuvant tamoxifen in breast cancer patients with various hormone receptor statuses. Methods: Typically, 1,260 female breast cancer patients were recruited in this study. The correlation between estrogen receptor (ER)/progesterone receptor (PR) phenotypes and clinical characteristics was investigated, and the survival rate was assessed after 5-year follow-up. Results: The 5-year overall survival (85%) was better in women under the age of 50 years. Patients with ER+/PR+ tumors had a better 5-year survival rate (94%); those with ER-/PRtumors experienced the worst outcome (74% survival rate); whereas singlepositive cases were in between. In 97 out of 128 patients with ER-/PR+ tumors, tamoxifen was given as adjuvant hormonal therapy, and it increased the survival benefit in the lower grade group in terms of overall survival and disease-free survival (p= 0.01 and p=0.03, respectively). Conclusion: For high-grade tumors with ER-/PR+, adjuvant tamoxifen therapy may have no survival benefit, whereas for the patients with low-grade ER-/ PR+ tumors, adjuvant tamoxifen therapy is highly suggestive.

KW - Breast carcinoma

KW - Estrogen receptor

KW - Progesterone receptor

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=84867689892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867689892&partnerID=8YFLogxK

U2 - 10.4048/jbc.2012.15.3.288

DO - 10.4048/jbc.2012.15.3.288

M3 - Article

C2 - 23091541

AN - SCOPUS:84867689892

VL - 15

SP - 288

EP - 295

JO - Journal of Breast Cancer

JF - Journal of Breast Cancer

SN - 1738-6756

IS - 3

ER -